For the first time in years, a state has acted to allow its citizens to purchase prescription drugs by mail from other countries. The idea is to take advantage of those nations' lower prices, which can be half the cost of those at American pharmacies.
The Food and Drug Administration Thursday evening approved over-the-counter sale, with no age restrictions, of Plan B One-Step. That's the morning-after pill whose status has been the subject of a dozen years of political wrangling and legal dispute.
When the maker of a brand-name drug pays a maker of generic drugs to not produce a lower-priced version of their product, the Federal Trade Commission can challenge the arrangement on antitrust grounds, the Supreme Court ruled Monday. The ruling may end the era of what regulators call "pay-for-delay" deals.
The justices voted 5-3 to allow a case to go forward in which the FTC is challenging one of many such deals. Several companies are involved in the case, including Solvay Pharmaceuticals, maker of AndroGel, and generic-drug maker Actavis.
An obviously unhappy Judge Edward Korman has approved the Obama administration's proposal to make just one formulation of the morning-after birth control pill available over the counter without age restrictions.
But in a testily worded six-page memorandum, the federal district judge made it clear he is not particularly pleased with the outcome. He has been overseeing the case in one way or another for more than eight years.